Canurta Showcases ALS and Neurodegenerative Research at Global Summits and Expands Scientific Leadership

Research Presentation at ALS Drug Development Summit in Boston

On May 26, at the ALS Drug Development Summit in Boston, our CEO, Akeem Gardner, presented an overview of Canurta’s latest findings titled "Pre-Clinical Research with a First-In-Class ALS Therapy Formulation." The research poster highlighted our preclinical work and innovative approach to addressing Amyotrophic Lateral Sclerosis (ALS) through our drug candidate CNR-401, which offers a polypharmacy approach to the complex nature of ALS.

View Research Poster

Event Insights

Highlighting Neurodegenerative Disease Research at the CannMedTM 24 Innovation & Investment Summit

On May 14, at the CannMedTM 24 Innovation & Investment Summit at Marco Island, Florida, our CEO, Akeem Gardner, captivated attendees with his presentation on The Effect of Cannflavins on Mitigating Motor Neuron Disease. The presentation highlighted the significant strides we are making in the fight against neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS).

Gardner detailed how the therapeutic potential of phytochemicals from cannabis, including cannflavins and cannabinoids, have shown promising initial results in reducing neuroinflammation—a key factor in neurodegenerative diseases—through their action on specific enzymes linked to neurodegenerative processes.

Read more about our pioneering research and the impact of these phytochemicals on neurodegenerative diseases through the link below.

Canurta Therapeutics Participates in EFFERVESCENCE—The Future of Life Sciences Conference

Our Research Associate, Kelly Boddington, participated in the EFFERVESCENCE—The Future of Life Sciences Conference in Montreal. This premier North American event showcased current and future trends in life sciences. This platform fostered insightful discussions and offered invaluable opportunities for establishing new partnerships. We are delighted to have participated and built meaningful connections at this influential conference.

Canurta Therapeutics Features in the BIOTECanada’s Insights Magazine

Canurta Therapeutics was featured in BIOTECanada’s spring issue of Insights magazine, dedicated to showcasing the best of Canadian biotechnology. The magazine’s latest issue features an exclusive interview with our CEO Akeem Gardner, detailing his journey to establishing Canurta and an overview of our lead asset, CNR 401, for Amyotrophic lateral sclerosis (ALS) treatment.

Insight Magazine

Canurta Therapeutics Announces Participation in the 2024 ALS Canada Pull to End Amyotrophic Lateral Sclerosis (ALS)

Canurta Therapeutics is thrilled to announce our return to the 2024 ALS Canada Pull to End ALS event at York University on October 19. Canurta’s team will once again take on the challenge of pulling a 42,000-lb truck over 100 metres to support the ALS community. This year, we aim to surpass our previous fundraising goal by raising $5000. However, we need your support to make this possible. Your donations will sustain vital community-based support services and advance research through the ALS society of Canada Research Program.

Let us pull together to end ALS. We invite you to join us in making a difference by donating today through the link below.

Canurta's May Milestones

Research & Development: Positive results for two of our assets in anti-anxiety screening assays in zebrafish models.

Bioinformatics: Our bioinformatics team leveraged AnswerALS differential expression analysis for biomarker discovery and reviewed the role of bitter taste receptors in neurodegenerative disorders. Reviewing literature about their presence in the brainstem, the druggability of these receptors for treating neurodegenerative diseases, and the regulatory mechanisms of transport of polyphenolic compounds by these receptors. This research opens promising avenues for developing innovative therapeutic treatments.